Literature DB >> 20697839

Bilateral ocular involvement as a presentation of Waldenström's macroglobulinemia.

José Verdú1, Raquel Andrés, José Luis Sánchez-Majano, José Antonio Fernández.   

Abstract

We describe a 54 years old female with Waldenstrom's macroglobulinemia who presented with a bilateral ocular involvement. Ophthalmic involvement in Waldenstrom's macroglobulinemia is very rare. In addition, to our knowledge, there are only a few reports in the literature in which a primary diagnosis was made on the basis of ocular involvement. Diagnosis of malignancy in our case was established on the basis of the presence of small lymphocytes in fine-needle aspiration cytology from the orbital mass and typical bone marrow aspiration immunophenotype for Waldenstrom's macroglobulinemia.

Entities:  

Mesh:

Year:  2010        PMID: 20697839     DOI: 10.1007/s12032-010-9648-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  4 in total

1.  Pathophysiology of Waldenström's macroglobulinemia.

Authors:  Marvin J Stone; Virginia Pascual
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

2.  Bilateral orbital tumor formation and isolated facial palsy in Waldenstrom's macroglobulinemia.

Authors:  Sushil Kumar; Sima Das; J L Goyal; D Chauhan; V Sangit
Journal:  Int Ophthalmol       Date:  2007-02-16       Impact factor: 2.031

3.  Nephrotic syndrome and acute renal failure in non-Hodgkin lymphoplasmacytic lymphoma.

Authors:  Natasa Colović; Tatjana Terzić; Bosko Andelić; Mirjana Sretenović; Biljana Mihaljević; Jasmina Marković Lipkovski; Milica Colović
Journal:  Med Oncol       Date:  2008-01-24       Impact factor: 3.064

4.  Case report: bilateral simultaneous central retinal vein occlusion in Waldenström's macroglobulinemia.

Authors:  Bhuvan Chanana; Nitin Gupta; Raj Vardhan Azad
Journal:  Optometry       Date:  2009-07
  4 in total
  1 in total

1.  [Retinal manifestation in hematological diseases].

Authors:  M Rehak; N Feltgen; P Meier; P Wiedemann
Journal:  Ophthalmologe       Date:  2018-09       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.